Logo

NUVL

Nuvalent, Inc.

NUVL

Nuvalent, Inc. • NASDAQ
$109.35 ▲ 0.27% (+0.29)
Market Cap $7.95 B
52w High $112.88
52w Low $55.53
Dividend Yield 0%
P/E -20.52
Volume 258.35K
Outstanding Shares 72.71M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $112.696M ▲ $-122.437M ▼ 0% $-1.7 ▼ $-122.305M ▼
Q2-2025 $0 $104.571M ▲ $-99.653M ▼ 0% $-1.39 ▼ $-104.571M ▼
Q1-2025 $0 $94.812M ▲ $-84.582M ▼ 0% $-1.18 ▼ $-94.812M ▼
Q4-2024 $0 $86.299M ▲ $-74.763M ▲ 0% $-1.05 ▲ $-86.299M ▼
Q3-2024 $0 $76.331M $-84.345M 0% $-1.28 $-76.331M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $943.103M ▼ $979.91M ▼ $134.511M ▲ $845.399M ▼
Q2-2025 $1.006B ▼ $1.041B ▼ $100.801M ▲ $939.742M ▼
Q1-2025 $1.073B ▼ $1.106B ▼ $94.749M ▲ $1.011B ▼
Q4-2024 $1.118B ▼ $1.142B ▼ $71.96M ▲ $1.07B ▼
Q3-2024 $1.168B $1.189B $67.732M $1.121B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-122.437M ▼ $-70.462M ▲ $53.971M ▼ $4.773M ▼ $-11.718M ▼ $-70.462M ▲
Q2-2025 $-99.653M ▼ $-76.598M ▼ $77.478M ▲ $5.755M ▲ $6.635M ▲ $-76.598M ▼
Q1-2025 $-84.582M ▼ $-54.821M ▲ $25.417M ▲ $4.548M ▼ $-24.856M ▲ $-54.821M ▲
Q4-2024 $-74.763M ▲ $-62M ▼ $-170.045M ▲ $8.492M ▼ $-223.553M ▼ $-62M ▼
Q3-2024 $-84.345M $-45.817M $-212.906M $550.267M $291.544M $-45.817M

Five-Year Company Overview

Income Statement

Income Statement Nuvalent is still a pure research-stage company, with no product revenue yet and steadily rising losses as it invests heavily in clinical trials and drug development. The pattern shows operating and net losses widening over time, which is typical for a clinical‑stage biotech but also means the business is entirely dependent on future approvals and partnerships to eventually support itself. Per‑share losses have deepened as spending has ramped up, reflecting a clear “growth and build” phase rather than any focus on profitability. Overall, the income statement tells the story of an emerging oncology platform still firmly in the investment phase.

Balance Sheet

Balance Sheet The balance sheet shows a company funded almost entirely with shareholder equity, with no financial debt and a growing base of assets over the past few years. Cash levels have fluctuated, likely reflecting periodic capital raises followed by deployment of funds into R&D and other operating needs, while total assets and equity have increased as the company scales. The absence of borrowings reduces financial risk, but the business remains reliant on its cash and investment balances to fund ongoing losses. In short, Nuvalent has a clean, equity‑funded balance sheet, but one that must be supported by continued access to capital until products begin to generate revenue.

Cash Flow

Cash Flow Cash flows highlight a consistent cash burn from operations, driven by research, clinical development, and corporate build‑out, with no offsetting inflows from product sales. Free cash flow is negative and closely tracks operating cash outflow, as the company has minimal spending on physical assets and is largely investing in people, trials, and intellectual property. This pattern is normal for a clinical‑stage biotech but underscores that Nuvalent’s runway is finite and will depend on its existing cash, potential milestone or partnership payments, and future financing activity. The cash flow profile is that of an R&D engine, not yet a commercial business.

Competitive Edge

Competitive Edge Nuvalent is carving out a focused position in precision oncology, concentrating on targeted kinase inhibitors for lung cancer patients who often run out of options due to resistance or brain metastases. Its approach emphasizes highly selective, brain‑penetrant molecules designed to avoid known toxicity issues, which could differentiate its drugs from existing treatments if clinical data continue to be supportive. The company’s lead programs in ROS1‑, ALK‑, and HER2‑altered non‑small cell lung cancer go after well‑validated targets but aim to offer better durability, safety, and central nervous system control than current standards. That said, it operates in a crowded field against large, well‑resourced pharmaceutical players, so clinical outcomes, safety profiles, and regulatory success will be critical in determining how strong its eventual market position becomes.

Innovation and R&D

Innovation and R&D Innovation is the core of Nuvalent’s story: it leverages structure‑based drug design to craft highly selective kinase inhibitors that address resistance mutations and penetrate the brain while intentionally avoiding off‑target pathways linked to side effects. The pipeline is relatively concentrated but deep, with three main clinical candidates each tailored to specific genetic drivers in lung cancer and designed to improve both efficacy and tolerability versus legacy drugs. R&D spending has been ramping up to support multiple trials, reflecting management’s commitment to building a broader platform rather than a single‑asset company. The long‑term value of this R&D effort depends heavily on upcoming clinical readouts, regulatory milestones, and the company’s ability to keep identifying new high‑value targets.

Summary

Nuvalent is an early‑stage oncology company with no revenues yet and a financial profile dominated by R&D spending, operating losses, and negative cash flow, all funded primarily through equity and a debt‑free balance sheet. Its investment case centers on a specialized drug design platform and a focused pipeline seeking to address key gaps in existing lung cancer treatments, particularly resistance and brain metastases. The company’s scientific strategy and initial clinical traction suggest meaningful potential, but there remains substantial uncertainty around trial outcomes, regulatory decisions, timing of any future commercialization, and ongoing funding needs. Overall, Nuvalent looks like a classic high‑innovation, high‑risk biotech story, where scientific and regulatory milestones will be the main drivers of future prospects.

NEWS

November 26, 2025 · 6:30 AM UTC

Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference

Read more

November 24, 2025 · 4:01 PM UTC

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders

Read more

November 19, 2025 · 4:19 PM UTC

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Read more

November 18, 2025 · 11:50 PM UTC

Nuvalent Announces Pricing of Public Offering of Common Stock

Read more

November 17, 2025 · 4:01 PM UTC

Nuvalent Announces Public Offering of Common Stock

Read more